News FDA Extends Review of Ofatumumab for Relapsing MS to September FDA Extends Review of Ofatumumab for Relapsing MS to September by Marisa Wexler, MS | June 4, 2020 Share this article: Share article via email Copy article link The U.S. Food and Drug Administration (FDA) is extending its review of Novartis‘Ā ofatumumab, a possible self-administered injection therapy for relapsingĀ multiple sclerosis (MS), the company announced. Originally expected in June, the FDA decision is now expected in September. “Novartis will continue to work with the FDA to complete the review as soon as possible,” Marie-France Tschudin, president of Novartis Pharmaceuticals, said in aĀ press release. “We are well prepared and ready to launch ofatumumab upon approval. We are committed to the MS community and look forward to bringing this important advancement to patients with MS,” Tschudin added. Ofatumumab is an antibody therapy that works by binding to CD20, a protein present on the surface of immuneĀ B-cells. By binding CD20, ofatumumab targets B-cells for destruction, which is believed to reduce inflammation in theĀ central nervous system (the brain and spinal cord). Ofatumumab is approved in the U.S. to treat certain blood cancers under the brand nameĀ Arzerra. Ofatumumab is different from other CD20-targeting therapies for MS in that it is designed to be self-administered once a month using an autoinjector pen, rather than through an infusion in a hospital setting. The therapy is being developed as a 20 mg under-the-skin (subcutaneous) injection. Novartis submitted a supplemental biologics license application (sBLA) to the FDA in late February. A BLA covers medications, like antibodies, that are manufactured with the use of living cells and are known as biologic products. In contrast, an investigational new drug application is for chemicals with a known structure that can be synthesized without using living cells. Novartis also submitted a marketing authorization application to theĀ European Medicines Agency (EMA) at the same time. A decision from the EMA is expected in mid-2021. These regulatory submissions are supported by positive data from the Phase 3 clinical trials ASCLEPIOS I (NCT02792218) and ASCLEPIOS II (NCT02792231). Collectively, these trials enrolled 1,882 people with relapsing MS, including relapsing-remitting MSĀ (RRMS) and activeĀ secondary progressive MSĀ (SPMS). Trial participants were randomly assigned to either ofatumumab (20 mg injections once a month) or Aubagio (14 mg oral capsules taken daily) for 30 months. Aubagio (teriflunomide) is an approved MS medication marketed by Sanofi Genzyme. Results from the trials demonstrated that the average annual relapse rate was more than 50% lower in patients given ofatumumab than in those given Aubagio ā 0.11 vs. 0.22 relapses/year in ASCLEPIOS I, and 0.10 vs. 0.25 relapses/year in ASCLEPIOS II. Ofatumumab also led to significant reductions in the number of active brain lesions, and in the risk of disability progression after three and six months. Ofatumumab was originally developed by GenmabĀ and licensed to GlaxoSmithKline; Novartis obtained all rights to ofatumumab in December 2015. Print This Page About the Author Marisa Wexler, MS Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America. Tags ASCLEPIOS, CD20, FDA, Novartis, Ofatumumab, review
April 26, 2024 News by Margarida Maia, PhD Employment, income drop steadily over 2 decades after onset of MS
April 26, 2024 News by Marisa Wexler, MS Machine learning model predicts CIS to MS conversion risk: Study
April 25, 2024 Columns by Benjamin Hofmeister Finding safety while living with the constant threat of MS progression